This effect did not exhibit any association with cancer cell response to HER2-therapy since both cancer cells with low (EFM192) or high (HCC1569) lapatinib AUC values exhibited similar sensitivity to tiplaxtinin. This evidence concerns the gene ERBB2 and cancer.